Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination chemotherapy studies with gemcitabine

C J van Moorsel1, G Veerman, A M Bergman

  • 1Department of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.

Seminars in Oncology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

Clinical genitourinary cancer·2024
Same author

Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.

Journal of cancer research and clinical oncology·2022
Same author

Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.

International journal of radiation oncology, biology, physics·2022
Same author

A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships.

European journal of medicinal chemistry·2022
Same author

[The development of a rational national MDMA policy and its relevance for psychiatry].

Tijdschrift voor psychiatrie·2021
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Gemcitabine combined with cisplatin, etoposide, or mitomycin C shows synergistic anticancer effects in vitro and in vivo. Optimal drug scheduling is crucial for maximizing the antitumor activity of gemcitabine combinations.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Gemcitabine is an effective antineoplastic agent against various cancers.
  • Gemcitabine has a favorable toxicity profile, making it suitable for combination therapies.
  • Established anticancer agents like cisplatin, etoposide, and mitomycin C are used against similar cancer types.

Purpose of the Study:

  • To investigate the in vitro and in vivo efficacy of gemcitabine in combination with cisplatin, etoposide, and mitomycin C.
  • To explore the synergistic potential and mechanisms of action for these drug combinations.
  • To determine the impact of drug scheduling on the overall antitumor activity.

Main Methods:

  • In vitro drug exposure of cancer cell lines (ovarian and non-small cell lung cancer) to gemcitabine and other agents.

Related Experiment Videos

  • Simultaneous and sequential drug administration protocols were employed.
  • In vivo studies using Lewis lung tumor models to assess combination efficacy.
  • Analysis of drug accumulation, DNA double-strand breaks, and platinum adducts.

    • Main Results:

    • Synergistic anticancer effects were observed for several gemcitabine combinations in vitro, particularly with cisplatin and etoposide.
    • Gemcitabine and cisplatin combination demonstrated enhanced antitumor activity in vivo against Lewis lung tumors.
    • Etoposide combined with gemcitabine significantly increased DNA double-strand breaks, especially when administered sequentially.
    • Drug scheduling significantly influenced the observed synergistic effects.

    Conclusions:

    • Gemcitabine is a promising agent for combination chemotherapy due to its synergistic potential with various anticancer drugs.
    • The combination of gemcitabine with cisplatin, etoposide, or mitomycin C can enhance therapeutic outcomes.
    • Schedule-dependent synergism highlights the importance of optimized treatment regimens for gemcitabine-based combinations.